Cara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.49), $0.02 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $6.17 million versus the consensus estimate of $4.95 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.